All In Biotech

Drug Trial Radar · NCT04151212

A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration

A Phase I Clinical Trial for BAT5906(Single-dose;for Injection) on Safety and Pharmacokinetics for Patients With Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Oct 30, 2018

Primary completion

Feb 28, 2021

Study completion Apr 30, 2021

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Nov 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.

Conditions

  • Age-related Macular Degeneration

Interventions

  • BAT5906 injectionDrug

    Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity(DLT)Time frame: 2 weeks
  2. Maximum tolerated dosed(MTD)Time frame: 0-70days
  3. Area under the curve(AUC0-t, AUC0-inf)Time frame: 0-70days
  4. Maximum serum drug concentration(Cmax)Time frame: 0-70days
  5. Half-life period(t1/2)Time frame: 0-70days
  6. Maximum serum drug time(Tmax)Time frame: 0-70days
  7. Plasma clearance(CL)Time frame: 0-70days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.